FierceBiotech 16. Apr. 2026 Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
FierceBiotech 6. Apr. 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech 1. Apr. 2026 Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
FierceBiotech 1. Apr. 2026 Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
FierceBiotech 23. März 2026 Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
FierceBiotech 19. März 2026 Pfizer adds to Seagen scrap heap with another early cancer candidate cull
FierceBiotech 12. März 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
FierceBiotech 4. März 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 25. Feb. 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
FierceBiotech 6. Feb. 2026 Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
FierceBiotech 4. Feb. 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 3. Feb. 2026 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
FierceBiotech 3. Feb. 2026 Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
FierceBiotech 21. Jan. 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech 20. Jan. 2026 Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
FierceBiotech 9. Jan. 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
FierceBiotech 15. Dez. 2025 Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts